Pharmacologic Management of Excessive Daytime Sleepiness

Shinichi Takenoshita; Seiji Nishino

doi:10.1016/j.jsmc.2017.03.019

Pharmacologic Management of Excessive Daytime Sleepiness

Sleep Med Clin. 2017 Sep;12(3):461-478. doi: 10.1016/j.jsmc.2017.03.019. Epub 2017 Jun 7.

Authors

Shinichi Takenoshita¹, Seiji Nishino²

Affiliations

¹ Sleep and Circadian Neurobiology Laboratory, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford University, Palo Alto, CA, USA.
² Sleep and Circadian Neurobiology Laboratory, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford University, Palo Alto, CA, USA. Electronic address: nishino@stanford.edu.

PMID: 28778242
DOI: 10.1016/j.jsmc.2017.03.019

Abstract

Excessive daytime sleepiness (EDS) is related to medical and social problems, including mental disorders, physical diseases, poor quality of life, and so forth. According to the International Classification of Sleep Disorders, Third Edition, diseases that result from EDS are narcolepsy type 1, narcolepsy type 2, idiopathic hypersomnia, hypersomnia due to a medical disorder, and others. EDS is usually treated using amphetamine-like central nervous system stimulants or modafinil and its R-enantiomer, armodafinil, wake-promoting compounds unrelated to amphetamines; a variety of new drugs are under development. The side effects of some stimulants are potent and careful selection and management are required.

Keywords: Excessive daytime sleepiness; Idiopathic hypersomnia; Narcolepsy; Stimulants.

Publication types

Review

MeSH terms

Central Nervous System Stimulants / pharmacology*
Disorders of Excessive Somnolence / drug therapy*
Disorders of Excessive Somnolence / physiopathology
Humans

Substances

Central Nervous System Stimulants